M
Michael Millward
Researcher at University of Texas MD Anderson Cancer Center
Publications - 2
Citations - 925
Michael Millward is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Survival rate & Docetaxel. The author has an hindex of 1, co-authored 2 publications receiving 903 citations.
Papers
More filters
Journal ArticleDOI
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
Frank V. Fossella,José Rodrigues Pereira,Joachim von Pawel,Anna Pluzanska,Vera Gorbounova,E. Kaukel,K. Mattson,Rodryg Ramlau,Aleksandra Szczesna,Panagiotis Fidias,Michael Millward,Chandra P. Belani +11 more
TL;DR: DC resulted in a more favorable overall response and survival rate than VC, demonstrating that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
Randomized, M ultinational, P hase I II S tudy o f D ocetaxel P lus Platinum C ombinations V ersus V inorelbine P lus C isplatin f or Advanced N on-Small-Cell L ung C ancer: T he T AX 3 26 Study G roup
Frank V. Fossella,José Rodrigues Pereira,Joachim von Pawel,Anna Pluzanska,Vera Gorbounova,E. Kaukel,K. Mattson,Aleksandra Szcze,Panagiotis Fidias,Michael Millward,Chandra P. Belani +10 more
TL;DR: In this article, the authors investigated whether a combination of docetaxel plus platinum regimens improved survival and affect quality of life (QoL) in advanced non-small-cell lung cancer (NSCLC) compared with vinorelbine plus cisplatin as first-line chemotherapy.